181 related articles for article (PubMed ID: 20051276)
21. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant.
Saul A; Lawrence G; Smillie A; Rzepczyk CM; Reed C; Taylor D; Anderson K; Stowers A; Kemp R; Allworth A; Anders RF; Brown GV; Pye D; Schoofs P; Irving DO; Dyer SL; Woodrow GC; Briggs WR; Reber R; Stürchler D
Vaccine; 1999 Aug; 17(23-24):3145-59. PubMed ID: 10462251
[TBL] [Abstract][Full Text] [Related]
22. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.
Ellis RD; Mullen GE; Pierce M; Martin LB; Miura K; Fay MP; Long CA; Shaffer D; Saul A; Miller LH; Durbin AP
Vaccine; 2009 Jun; 27(31):4104-9. PubMed ID: 19410624
[TBL] [Abstract][Full Text] [Related]
23. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
Tamminga C; Sedegah M; Maiolatesi S; Fedders C; Reyes S; Reyes A; Vasquez C; Alcorta Y; Chuang I; Spring M; Kavanaugh M; Ganeshan H; Huang J; Belmonte M; Abot E; Belmonte A; Banania J; Farooq F; Murphy J; Komisar J; Richie NO; Bennett J; Limbach K; Patterson NB; Bruder JT; Shi M; Miller E; Dutta S; Diggs C; Soisson LA; Hollingdale MR; Epstein JE; Richie TL
Hum Vaccin Immunother; 2013 Oct; 9(10):2165-77. PubMed ID: 23899517
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
[TBL] [Abstract][Full Text] [Related]
25. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques.
Langermans JA; Schmidt A; Vervenne RA; Birkett AJ; Calvo-Calle JM; Hensmann M; Thornton GB; Dubovsky F; Weiler H; Nardin E; Thomas AW
Vaccine; 2005 Sep; 23(41):4935-43. PubMed ID: 15998554
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
27. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
Chuang I; Sedegah M; Cicatelli S; Spring M; Polhemus M; Tamminga C; Patterson N; Guerrero M; Bennett JW; McGrath S; Ganeshan H; Belmonte M; Farooq F; Abot E; Banania JG; Huang J; Newcomer R; Rein L; Litilit D; Richie NO; Wood C; Murphy J; Sauerwein R; Hermsen CC; McCoy AJ; Kamau E; Cummings J; Komisar J; Sutamihardja A; Shi M; Epstein JE; Maiolatesi S; Tosh D; Limbach K; Angov E; Bergmann-Leitner E; Bruder JT; Doolan DL; King CR; Carucci D; Dutta S; Soisson L; Diggs C; Hollingdale MR; Ockenhouse CF; Richie TL
PLoS One; 2013; 8(2):e55571. PubMed ID: 23457473
[TBL] [Abstract][Full Text] [Related]
28. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
Younis S; Faber BW; Kocken CHM; Remarque EJ
BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults.
Hu J; Chen Z; Gu J; Wan M; Shen Q; Kieny MP; He J; Li Z; Zhang Q; Reed ZH; Zhu Y; Li W; Cao Y; Qu L; Cao Z; Wang Q; Liu H; Pan X; Huang X; Zhang D; Xue X; Pan W
PLoS One; 2008 Apr; 3(4):e1952. PubMed ID: 18398475
[TBL] [Abstract][Full Text] [Related]
30. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.
Herrera S; Fernández OL; Vera O; Cárdenas W; Ramírez O; Palacios R; Chen-Mok M; Corradin G; Arévalo-Herrera M
Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):12-20. PubMed ID: 21292873
[TBL] [Abstract][Full Text] [Related]
31. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults.
Remarque EJ; Roestenberg M; Younis S; Walraven V; van der Werff N; Faber BW; Leroy O; Sauerwein R; Kocken CH; Thomas AW
PLoS One; 2012; 7(6):e38898. PubMed ID: 22768052
[TBL] [Abstract][Full Text] [Related]
32. Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
Elias SC; Choudhary P; de Cassan SC; Biswas S; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Hodgson SH; Duncan CJ; Hill AV; Draper SJ
Immunology; 2014 Apr; 141(4):628-44. PubMed ID: 24303947
[TBL] [Abstract][Full Text] [Related]
33. Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02
Berry AA; Gottlieb ER; Kouriba B; Diarra I; Thera MA; Dutta S; Coulibaly D; Ouattara A; Niangaly A; Kone AK; Traore K; Tolo Y; Mishcherkin V; Soisson L; Diggs CL; Blackwelder WC; Laurens MB; Sztein MB; Doumbo OK; Plowe CV; Lyke KE
Malar J; 2019 Jan; 18(1):13. PubMed ID: 30658710
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
Genton B; Al-Yaman F; Anders R; Saul A; Brown G; Pye D; Irving DO; Briggs WR; Mai A; Ginny M; Adiguma T; Rare L; Giddy A; Reber-Liske R; Stuerchler D; Alpers MP
Vaccine; 2000 May; 18(23):2504-11. PubMed ID: 10775784
[TBL] [Abstract][Full Text] [Related]
35. Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians.
Dicko A; Diemert DJ; Sagara I; Sogoba M; Niambele MB; Assadou MH; Guindo O; Kamate B; Baby M; Sissoko M; Malkin EM; Fay MP; Thera MA; Miura K; Dolo A; Diallo DA; Mullen GE; Long CA; Saul A; Doumbo O; Miller LH
PLoS One; 2007 Oct; 2(10):e1045. PubMed ID: 17940609
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children.
Dicko A; Sagara I; Ellis RD; Miura K; Guindo O; Kamate B; Sogoba M; Niambelé MB; Sissoko M; Baby M; Dolo A; Mullen GE; Fay MP; Pierce M; Diallo DA; Saul A; Miller LH; Doumbo OK
PLoS One; 2008 Feb; 3(2):e1563. PubMed ID: 18270560
[TBL] [Abstract][Full Text] [Related]
37. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
[TBL] [Abstract][Full Text] [Related]
38. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.
Sedegah M; Tamminga C; McGrath S; House B; Ganeshan H; Lejano J; Abot E; Banania GJ; Sayo R; Farooq F; Belmonte M; Manohar N; Richie NO; Wood C; Long CA; Regis D; Williams FT; Shi M; Chuang I; Spring M; Epstein JE; Mendoza-Silveiras J; Limbach K; Patterson NB; Bruder JT; Doolan DL; King CR; Soisson L; Diggs C; Carucci D; Dutta S; Hollingdale MR; Ockenhouse CF; Richie TL
PLoS One; 2011; 6(10):e24586. PubMed ID: 22003383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]